Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $9.83
Previous CloseN/A
Volume1.36M
Average Volume (3M)4.39M
Market Cap
$1.35B
Enterprise Value$1.54B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding236,854,260
10 Day Avg. Volume3,667,710
30 Day Avg. Volume4,392,705
Standard Deviation0.22
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.98
Price to Cash Flow (P/CF)751.70
P/FCF Ratio1034.60
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.43
Enterprise Value/Ebitda-29.01
Forecast
1Y Price Target
$9.30Price Target Upside83.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Ardelyx News
PremiumCompany Announcements
Ardelyx (ARDX) Earnings Call: Strong Growth Amidst Challenges
PremiumCompany Announcements
Ardelyx Inc. Grapples with Trade Secret Risks Threatening Financial Stability
PremiumCompany Announcements
Ardelyx Reports Strong 2024 Financial Performance
---
Bulls Say, Bears Say
Bulls Say
Sales GrowthExpanded Ibsrela sales force is seeing year-over-year growth in early Q1.
Strategic OutlookArdelyx provided a comprehensive strategic update that reinforces conviction in their commercial execution and long-term growth potential for their two commercial assets, Ibsrela in IBS-C and Xphozah in hyperphosphatemia.
Bears Say
Medicare CoverageXPHOZAH is no longer available under Medicare Part D as of January 1, 2025.
---
Ownership Overview
2.69% Insiders
20.18% Mutual Funds
10.93% Other Institutional Investors
53.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $4.32 and its highest was $9.83 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.35B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is May 01, 2025 which is in 68 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Feb 20, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.004 by $0.016.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.1.
How many shares outstanding does Ardelyx have?
Ardelyx has 236,854,260 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0.02 in its last earnings report, beating expectations of $0.004. Following the earnings report the stock price went down -10.063%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
---
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.30 (83.79% Upside)
$9.30 (83.79% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 84%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 147.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.09%
12-Months-Change
Fundamentals
Return on Equity
-23.01%
Trailing 12-Months
Asset Growth
46.43%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
ARDX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Ardelyx demonstrated strong financial growth and successful product launches, particularly with IBSRELA and XPHOZAH, which led to significant revenue increases and a positive financial position. However, challenges such as the loss of Medicare Part D coverage for XPHOZAH and increased operational expenses present potential hurdles. Overall, the positive achievements appear to outweigh the lowlights.Read More>---
ARDX Stock 12 Month Forecast
Average Price Target
$9.30
▲(83.79% Upside)
Technical Analysis
Best Analysts Covering ARDX
1 Year
1 Year Success Rate
8/16 ratings generated profit
1 Year Average Return
+60.84%
reiterated a buy rating 4 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +60.84% per trade.
---